Business Context and Reporting Period
This Form 6-K filing by Dr. Reddy's Laboratories Limited (NYSE: RDY) serves as a notification of the submission of its Annual Report on Form 20-F. The filing covers the fiscal year ended March 31, 2010. The company is an emerging global pharmaceutical firm established in 1984, operating through three core businesses: Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products. Its primary markets include India, the US, UK, Germany, and Russia.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural announcement confirming the availability of the Form 20-F, which contains the detailed consolidated financial statements for the fiscal year ended March 31, 2010.
Material Changes
No material changes in financial performance or operations are detailed in this specific filing. The document solely announces the filing of the annual report and does not contain comparative financial data or analysis of changes versus prior periods.
Guidance, Outlook, and Risks
The press release included in the filing contains a standard disclaimer regarding forward-looking statements. Management notes that actual results may differ materially from expectations due to various risks, including:
- Changes in local and global economic conditions.
- The ability to successfully implement corporate strategy.
- Market acceptance and demand for products.
- Growth and expansion challenges.
- Technological changes.
- Exposure to market risks.
No specific financial guidance or outlook figures are provided in this text.
Investor Verification Checklist
- Verify the full consolidated financial statements by accessing the Form 20-F on the company's website (www.drreddys.com) under the "Investors" section or via the SEC EDGAR database.
- Confirm the fiscal year end date of March 31, 2010, when reviewing performance metrics.
- Review the detailed risk factors and management discussion within the full Form 20-F for specific operational challenges not summarized in this announcement.
- Contact investor relations (Kedar Upadhye or Milan Kalawadia) for hard copies of the report if required.